Supplemental Digital Content 1: Baseline demographic and clinical variables by AD risk factor status

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Obj-SCD-(N=494) | Obj-SCD+(N=260) | APOE ε4-(N=541) | APOE ε4+(N=269) | Tau-(N=343) | Tau+(N=243) | p-tau-(N=263) | p-tau+(N=323) | Aβ-(N=315) | Aβ+(N=271) |
|  | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
| Age | **72.95 (6.62)** | **74.33 (7.24)\*** | **74.30 (6.74)** | **72.28 (7.02)\*\*\*** | **71.92 (6.58)** | **74.52 (7.29)\*\*\*** | **71.59 (6.75)** | **74.15 (7.00)\*\*\*** | **72.06 (7.11)** | **74.09 (6.72)\*\*\*** |
| Education | 16.40 (2.72) | 16.20 (2.63) | 16.33 (2.73) | 16.13 (2.66) | 16.38 (2.63) | 16.17 (2.70) | 16.50 (2.56) | 16.12 (2.73) | 16.37 (2.58) | 16.20 (2.75) |
| Female, N (%) | **253 (51.2%)** | **111 (30.5%)\*** | 256 (47.3%) | 118 (43.9%) | 156 (45.5%) | 117 (48.1%) | 126 (47.9%) | 147 (45.5%) | 155 (49.2%) | 153 (43.5%) |
| FAQ | **0.47 (1.04)** | **0.75 (1.24)\*\*\*** | 1.18 (2.69) | 1.20 (2.41) | **0.98 (2.40)** | **1.52 (2.95)\*** | **0.99 (2.53)** | **1.38 (2.74)\*\*** | **0.78 (2.20)** | **1.17 (3.03)\*\*\*** |
| GDS | 1.17 (1.31) | 1.22 (1.37) | 1.18 (1.32) | 1.25 (1.33) | **1.34 (1.38)** | **1.11 (1.26)\*** | 1.33 (1.40) | 1.18 (1.28) | 1.20 (1.36) | 1.30 (1.31) |
| HIS | 0.53 (0.65) | 0.62 (0.67) | 0.59 (0.68) | 0.56 (0.65) | 0.61 (0.71) | 0.56 (0.64) | 0.62 (0.73) | 0.56 (0.64) | 0.55 (0.66) | 0.63 (0.69) |
| PP | 59.29 (14.45) | 61.18 (15.06) | 60.01 (14.27) | 60.44 (15.76) | **58.32 (14.40)** | **62.17 (14.87)\*\*** | **58.01 (14.22)** | **61.46 (14.94)\*\*** | 59.85 (14.48) | 59.99 (14.99) |
| MMSE | **28.92 (1.24)** | **28.37 (1.67)\*\*\*** | 28.68 (1.45) | 28.52 (1.66) | 28.80 (1.43) | 28.51 (1.58) | **28.89 (1.30)** | **28.51 (1.63)\*\*** | **28.87 (1.26)** | **28.46 (1.72)\*** |
| Obj-SCD+, N (%) | - | - | 164 (32.7%) | 95 (38.0%) | 104 (31.9%) | 84 (38.0%) | 77 (30.9%) | 111 (37.2%) | 86 (28.2%) | 102 (42.1%)\*\* |
| APOE ε4+, N (%) | 155 (31.4%) | 95 (36.7%) | - | - | **94 (27.4%)** | **100 (41.2%)\*\*\*** | **60 (22.8%)** | **134 (41.5%)\*\*\*** | **62 (19.7%)** | **132 (48.7%)\*\*\*** |
| t-tau+, N (%) | 137 (38.2%) | 84 (44.7%) | **143 (36.5%)** | **100 (51.5%)\*\*\*** | - | - | 0 (0.0%) | 243 (100%)\*\*\* | 121 (38.4%) | 122 (45.0%) |
| p-tau+, N (%) | 187 (34.2%) | 111 (59.0%) | **189 (48.2%)** | **134 (69.1%)\*\*\*** | **80 (23.3%)** | **243 (100%)\*\*\*** | - | - | **160 (50.8%)** | **163 (60.1%)\*** |
| Aβ+, N (%) | **140 (39.0%)** | **102 (54.3%)\*\*** | **139 (35.5%)** | **132 (68.0%)\*\*\*** | 149 (43.4%) | 122 (50.2%) | **108 (41.1%)** | **163 (50.5%)\*** | - | - |
| DM+, N (%) | 34 (6.9%) | 27 (10.4%) | 42 (7.8%) | 27 (3.3%) | 33 (9.6%) | 17 (7.0%) | 27 (10.3%) | 23 (7.1%) | 29 (9.2%) | 21 (7.7%) |
| Blood glucose | 99.93 (17.00) | 100.73 (16.28) | **99.48 (17.07)** | **102.41 (17.37)\*** | 101.23 (17.47) | 100.53 (17.54) | 100.34 (17.77) | 101.42 (17.38) | 101.27 (16.53) | 100.53 (18.71) |

Obj-SCD=Objectively-measured Subtle Cognitive Decline; APOE ε4=apolipoprotein E ε4; tau=total tau; p-tau=hyperphosphorylated tau; Aβ=β-amyloid; FAQ=Functional Activities Questionnaire; GDS=Geriatric Depression Scale; HIS=Hachinski Ischemia Scale; PP=pulse pressure; MMSE=Mini Mental State Exam; DM=Type II diabetes mellitus. Blood glucose (mg/dL) was available for 642 participants (DM- n=585, DM+ n=57), but the fasting period varied (as little as 4 hours). Bold values represent a significant difference between AD risk factor positive and negative groups.